Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
about
Bcl-2 antagonists: a proof of concept for CLL therapyTargeting the apoptosis pathway in hematologic malignanciesSmall molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapyThe Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studiesInhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma [corrected] cells.Programmed cell death pathways and current antitumor targets.An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma.Targeted treatment and new agents in diffuse large B cell lymphoma.Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.Recent advances in gossypol derivatives and analogs: a chemistry and biology view.Physiological and Pharmacological Control of BAK, BAX, and Beyond.Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors.Apogossypolone (ApoG2) induces ROS-dependent apoptosis and reduces invasiveness of PC12 cells in vitro and in vivo.Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells.
P2860
Q26823996-965A12D3-9797-406B-A70C-B94CEFC87E53Q27024422-8C252907-C38C-46F1-B14A-6FACCA707517Q35099238-BA5537A7-2F1B-4268-8A38-69012E219BD9Q35180339-D54054A4-DC7A-417D-8C4D-7FFC39A78561Q35980997-FBF7C56A-53D2-4534-B177-359203EBCC20Q36541458-D0CE5F6E-B0D1-490F-B2F6-0800B2E5349EQ37073671-C13D9FF5-0F2B-41F0-AD38-89AA25018E4EQ37466253-AF59FB57-268F-414F-9848-414AA10FB0FBQ37477829-C41F4CC6-7D92-4ECA-BACB-50FC933F8BB3Q37520553-290D0654-6ACC-4FCE-BDD0-95F3DB1D5704Q37766121-6C7CC5E1-3D3C-4112-BAFA-C30F32F44FEFQ38442515-CB04D41F-B572-4E23-9433-8EADFC96A13CQ38655357-820829FF-9CE6-498C-95DA-BC3FB6322853Q38921056-0BF8E5DD-0752-492C-9CA9-178F69683147Q42061450-CB10EFD8-2E3D-41EF-B9CF-BA7DC4A9A0D7Q42068051-5548B8CA-759B-4A5F-804D-79E1D1C96644Q42773124-AF10EB75-FA7F-44BC-B31B-BD837E294543
P2860
Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Apogossypolone, a nonpeptidic ...... ma cells in vitro and in vivo.
@ast
Apogossypolone, a nonpeptidic ...... ma cells in vitro and in vivo.
@en
type
label
Apogossypolone, a nonpeptidic ...... ma cells in vitro and in vivo.
@ast
Apogossypolone, a nonpeptidic ...... ma cells in vitro and in vivo.
@en
prefLabel
Apogossypolone, a nonpeptidic ...... ma cells in vitro and in vivo.
@ast
Apogossypolone, a nonpeptidic ...... ma cells in vitro and in vivo.
@en
P2093
P2860
P356
P1476
Apogossypolone, a nonpeptidic ...... ma cells in vitro and in vivo.
@en
P2093
Alan A Arnold
Amro Aboukameel
Ayad Al-Katib
Dajun Yang
Jianyong Chen
Ramzi M Mohammad
Sanjeev Banerjee
Shaomeng Wang
Xiaolan Ling
P2860
P304
P356
10.4161/CBT.7.9.6430
P577
2008-09-04T00:00:00Z